Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels

Biochemical and Biophysical Research Communications

Volumn 424, Issue 4, 2012, Pages 786-792

  Zhang, Ren ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C19ORF80; Gm6484; Lipasin; Lipid; Triglyceride

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 3; ANGIOPOIETIN LIKE 4; LIPASIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; LIPID DIET; LIVER; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE;

AMINO ACID SEQUENCE; ANGIOPOIETINS; ANIMALS; CONSERVED SEQUENCE; DYSLIPIDEMIAS; EVOLUTION, MOLECULAR; HUMANS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; PROTEINS; TRIGLYCERIDES;

MUS;

EID: 84864809680     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.038     Document Type: Article

References (31)

1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
2. Taubes G. Demographics - as obesity rates rise, experts struggle to explain why. Science 1998, 280:1367-1368.
3. Popkin B.M., Doak C.M. The obesity epidemic is a worldwide phenomenon. Nutr. Rev. 1998, 56:106-114.
4. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004, 116:337-350.
5. Billington C.J., Epstein L.H., Goodwin N.J., Hill J.O., Pi-Sunyer J.X., Rolls B.J., Stern J., Wadden T.A., Weinsier R.L., Wilson G.T., Wing R.R., Yanovski S.Z., Hubbard V.S., Hoofnagle J.H., Everhart J., Harrison B. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch. Intern. Med. 2000, 160:898-904.
6. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 1999, 83:25F-29F.
7. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome - an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
8. Kennedy A.R., Pissios P., Otu H., Roberson R., Xue B., Asakura K., Furukawa N., Marino F.E., Liu F.F., Kahn B.B., Libermann T.A., Maratos-Flier E. A high-fat, ketogenic diet induces a unique metabolic state in mice. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1724-E1739.
9. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
10. Gupta R.K., Rosen E.D., Spiegelman B.M. Identifying novel transcriptional components controlling energy metabolism. Cell Metab. 2011, 14:739-745.
11. Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C., Stylianou I.M., Koseki M., Pirruccello J.P., Ripatti S., Chasman D.I., Willer C.J., Johansen C.T., Fouchier S.W., Isaacs A., Peloso G.M., Barbalic M., Ricketts S.L., Bis J.C., Aulchenko Y.S., Thorleifsson G., Feitosa M.F., Chambers J., Orho-Melander M., Melander O., Johnson T., Li X., Guo X., Li M., Shin Cho Y., Jin Go M., Jin Kim Y., Lee J.Y., Park T., Kim K., Sim X., Twee-Hee Ong R., Croteau-Chonka D.C., Lange L.A., Smith J.D., Song K., Hua Zhao J., Yuan X., Luan J., Lamina C., Ziegler A., Zhang W., Zee R.Y., Wright A.F., Witteman J.C., Wilson J.F., Willemsen G., Wichmann H.E., Whitfield J.B., Waterworth D.M., Wareham N.J., Waeber G., Vollenweider P., Voight B.F., Vitart V., Uitterlinden A.G., Uda M., Tuomilehto J., Thompson J.R., Tanaka T., Surakka I., Stringham H.M., Spector T.D., Soranzo N., Smit J.H., Sinisalo J., Silander K., Sijbrands E.J., Scuteri A., Scott J., Schlessinger D., Sanna S., Salomaa V., Saharinen J., Sabatti C., Ruokonen A., Rudan I., Rose L.M., Roberts R., Rieder M., Psaty B.M., Pramstaller P.P., Pichler I., Perola M., Penninx B.W., Pedersen N.L., Pattaro C., Parker A.N., Pare G., Oostra B.A., O'Donnell C.J., Nieminen M.S., Nickerson D.A., Montgomery G.W., Meitinger T., McPherson R., McCarthy M.I., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
12. Tang T., Li L., Tang J., Li Y., Lin W.Y., Martin F., Grant D., Solloway M., Parker L., Ye W., Forrest W., Ghilardi N., Oravecz T., Platt K.A., Rice D.S., Hansen G.M., Abuin A., Eberhart D.E., Godowski P., Holt K.H., Peterson A., Zambrowicz B.P., de Sauvage F.J. A mouse knockout library for secreted and transmembrane proteins. Nat. Biotechnol. 2010, 28:749-755.
13. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
14. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25:3389-3402.
15. Koishi R., Ando Y., Ono M., Shimamura M., Yasumo H., Fujiwara T., Horikoshi H., Furukawa H. Angptl3 regulates lipid metabolism in mice. Nat. Genet. 2002, 30:151-157.
16. Ono M., Shimizugawa T., Shimamura M., Yoshida K., Noji-Sakikawa C., Ando Y., Koishi R., Furukawa H. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J. Biol. Chem. 2003, 278:41804-41809.
17. Lee E.C., Desai U., Gololobov G., Hong S., Feng X., Yu X.C., Gay J., Wilganowski N., Gao C., Du L.L., Chen J., Hu Y., Zhao S., Kirkpatrick L., Schneider M., Zambrowicz B.P., Landes G., Powell D.R., Sonnenburg W.K. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 2009, 284:13735-13745.
18. Koster A., Chao Y.B., Mosior M., Ford A., Gonzalez-DeWhitt P.A., Hale J.E., Li D., Qiu Y., Fraser C.C., Yang D.D., Heuer J.G., Jaskunas S.R., Eacho P. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005, 146:4943-4950.
19. Cypess A.M., Lehman S., Williams G., Tal I., Rodman D., Goldfine A.B., Kuo F.C., Palmer E.L., Tseng Y., Doria A., Kolodny G.M., Kahn C.R. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 2009, 360:1509-1517.
20. Virtanen K.A., Lidell M.E., Orava J., Heglind M., Westergren R., Niemi T., Taittonen M., Laine J., Savisto N.J., Enerback S., Nuutila P. Brief report: functional brown adipose tissue in healthy adults. N. Engl. J. Med. 2009, 360:1518-1525.
21. Miida T., Hirayama S. Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events. Curr. Opin. Lipidol. 2010, 21:70-75.
22. Mattijssen F., Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim. Biophys. Acta 1821, 2012:782-789.
23. Willer C.J., Sanna S., Jackson A.U., Scuteri A., Bonnycastle L.L., Clarke R., Heath S.C., Timpson N.J., Najjar S.S., Stringham H.M., Strait J., Duren W.L., Maschio A., Busonero F., Mulas A., Albai G., Swift A.J., Morken M.A., Narisu N., Bennett D., Parish S., Shen H., Galan P., Meneton P., Hercberg S., Zelenika D., Chen W.M., Li Y., Scott L.J., Scheet P.A., Sundvall J., Watanabe R.M., Nagaraja R., Ebrahim S., Lawlor D.A., Ben-Shlomo Y., Davey-Smith G., Shuldiner A.R., Collins R., Bergman R.N., Uda M., Tuomilehto J., Cao A., Collins F.S., Lakatta E., Lathrop G.M., Boehnke M., Schlessinger D., Mohlke K.L., Abecasis G.R. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 2008, 40:161-169.
24. Kathiresan S., Willer C.J., Peloso G.M., Demissie S., Musunuru K., Schadt E.E., Kaplan L., Bennett D., Li Y., Tanaka T., Voight B.F., Bonnycastle L.L., Jackson A.U., Crawford G., Surti A., Guiducci C., Burtt N.P., Parish S., Clarke R., Zelenika D., Kubalanza K.A., Morken M.A., Scott L.J., Stringham H.M., Galan P., Swift A.J., Kuusisto J., Bergman R.N., Sundvall J., Laakso M., Ferrucci L., Scheet P., Sanna S., Uda M., Yang Q., Lunetta K.L., Dupuis J., de Bakker P.I., O'Donnell C.J., Chambers J.C., Kooner J.S., Hercberg S., Meneton P., Lakatta E.G., Scuteri A., Schlessinger D., Tuomilehto J., Collins F.S., Groop L., Altshuler D., Collins R., Lathrop G.M., Melander O., Salomaa V., Peltonen L., Orho-Melander M., Ordovas J.M., Boehnke M., Abecasis G.R., Mohlke K.L., Cupples L.A. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 2009, 41:56-65.
25. Romeo S., Pennacchio L.A., Fu Y., Boerwinkle E., Tybjaerg-Hansen A., Hobbs H.H., Cohen J.C. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 2007, 39:513-516.
26. Talmud P.J., Smart M., Presswood E., Cooper J.A., Nicaud V., Drenos F., Palmen J., Marmot M.G., Boekholdt S.M., Wareham N.J., Khaw K.T., Kumari M., Humphries S.E. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2319-2325.
27. Romeo S., Yin W., Kozlitina J., Pennacchio L.A., Boerwinkle E., Hobbs H.H., Cohen J.C. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 2009, 119:70-79.
28. Musunuru K., Pirruccello J.P., Do R., Peloso G.M., Guiducci C., Sougnez C., Garimella K.V., Fisher S., Abreu J., Barry A.J., Fennell T., Banks E., Ambrogio L., Cibulskis K., Kernytsky A., Gonzalez E., Rudzicz N., Engert J.C., DePristo M.A., Daly M.J., Cohen J.C., Hobbs H.H., Altshuler D., Schonfeld G., Gabriel S.B., Yue P., Kathiresan S. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 2010, 363:2220-2227.
29. Mandard S., Zandbergen F., van Straten E., Wahli W., Kuipers F., Muller M., Kersten S. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 2006, 281:934-944.
30. Desai U., Lee E.C., Chung K., Gao C., Gay J., Key B., Hansen G., Machajewski D., Platt K.A., Sands A.T., Schneider M., Van Sligtenhorst I., Suwanichkul A., Vogel P., Wilganowski N., Wingert J., Zambrowicz B.P., Landes G., Powell D.R. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc. Natl. Acad. Sci. USA 2007, 104:11766-11771.
31. Shimamura M., Matsuda M., Yasumo H., Okazaki M., Fujimoto K., Kono K., Shimizugawa T., Ando Y., Koishi R., Kohama T., Sakai N., Kotani K., Komuro R., Ishida T., Hirata K., Yamashita S., Furukawa H., Shimomura I. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 2007, 27:366-372.